Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 12/20 | 0.43 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4584452 | 0.93 | HTR6 (0.44) | PTGDR2RORC | |
| SCHEMBL13888089 | 0.89 | RORC (0.41) | L3MBTL1PTGDR2PTPN11RORC | |
| SCHEMBL8240222 | 0.84 | RORC (0.42) | RORC | |
| SCHEMBL4476147 | 0.83 | ROCK1 (0.55) | RORCCYP3A4ROCK1 | |
| SCHEMBL4478038 | 0.83 | L3MBTL1 (0.46) | L3MBTL1PTGDR2PTPN11 | |
| SCHEMBL8944259 | 0.80 | L3MBTL1 (0.67) | L3MBTL1PTGDR2PTPN11 | |
| SCHEMBL4583237 | 0.80 | PIK3C3 (0.45) | L3MBTL1RORC | |
| SCHEMBL10125133 | 0.79 | L3MBTL1 (0.45) | L3MBTL1RORCGRM4 | |
| SCHEMBL1666756 | 0.77 | L3MBTL1 (0.48) | L3MBTL1PTGDR2PTPN11 | |
| SCHEMBL14510800 | 0.77 | L3MBTL1 (0.41) | L3MBTL1RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514448-B2 | Azaindoles useful as inhibitors of rock and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1756108-A2 | AZAINDOLES USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20060003968-A1 | Azaindoles useful as inhibitors of rock and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2006-01-05 | — | — | US | disclosed |
| WO-2005103050-A2 | AZAINDOLES USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060003968-A1 | Azaindoles useful as inhibitors of rock and other protein kinases | ROCK2, ROCK1, TNK2 | L3MBTL1 3130/4885PTGDR2 1259/4885PTPN11 768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.